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An AssessMent of the econoMic iMPAct of the ADoPtion of A new 
MechAnicAl fixAtion Device Along with A new skirteD intrA-
PeritoneAl onlAy Mesh (iPoM) on hosPitAl costs of oPen ventrAl 
herniA rePAir surgeries
Panish J.M.1, Chekan E.2, Roy S.1
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Objectives: Demonstrating economic value of new products is important for hos-
pitals adoption. The combination of two devices: ETHICON SECURESTRAP® Open 
Absorbable Strap Fixation Device and ETHICON PHYSIOMESH™ Open Flexible 
Composite Mesh Device, offers a standardized approach to open IPOM repair 
of ventral hernia. This analysis assesses the potential economic value of using 
these devices when compared with other meshes and a hand-sutured fixation 
approach. MethOds: An economic model was developed to evaluate the budget 
impact to hospitals adopting ETHICON SECURESTRAP™ Open Fixation Device with 
ETHICON PHYSIOMESH™ Open in ventral hernia repair. A 1- to 3-year time horizon 
was included in the Excel-based model. An increasing utilization rate for ETHICON 
SECURESTRAP™ Open (20% - 60%), and ETHICON PHYSIOMESH™ Open (10% - 30%) 
was assumed over 3-year horizon. Costs of the mechanical fixation device, suture 
supplies, mesh, OR time, anesthesia time, and potentially avoided surgical site infec-
tions were considered. The differences in total costs were calculated. Results: 
Based on the model inputs, a 3-year total potential saving of $240,650 was estimated 
for 100 annual open ventral hernia surgeries using ETHICON SECURESTRAP™ Open 
Fixation Device versus suture of various meshes. Over three years, although the use 
of ETHICON SECURESTRAP™ Open Fixation Device added $54,600 in supplies costs, 
this was completely offset by potential savings in OR time costs ($167,520), potential 
reduction in avoided surgical site infection or seroma costs due to shorter operat-
ing room time ($126,903), and potential reduction in anesthesia costs ($17,189). 
Similarly, a savings of $40,108 was expected in the very first year. cOnclusiOns: 
This analysis represents the first economic evaluation of ETHICON SECURESTRAP™ 
Open Fixation Device with ETHICON PHYSIOMESH™ Open in open ventral hernia 
surgery. Adoption of the two devices would likely result in savings for hospitals, 
driven by shorter procedure time and related expected clinical benefits.
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Objectives: Peripheral artery disease affects 8-10 million U.S. adults and 50% 
involve femoropopliteal arteries. A novel treatment, the Lutonix®035 Drug Coated 
Balloon PTA catheter (DCB) is indicated for percutaneous transluminal angioplasty 
(PTA), after pre-dilatation, of de novo or restenotic lesions up to 150mm in length 
in native superficial femoral or popliteal arteries with reference vessel diameters 
of 4-6mm. These analyses estimated the potential cost impact of DCBs vs. current 
care. MethOds: These economic modeled analyses compared total costs with vs. 
without DCBs over one year in a real-world scenario treatment mix for femoro-
popliteal PAD; these analyses were not based upon head-to-head clinical compari-
sons. For the inpatient hospital perspective, DCBs were compared with PTA, bare 
metal stents (BMS), drug-eluting stents (DES), covered stents (CS), and atherectomy. 
For the outpatient perspective, DCBs plus short spot stents were compared with 
BMS, DES, CS, and atherectomy. Equal distribution of treatment options in a world 
with vs. without DCBs was assumed. Consumable device-related costs (based upon 
published costs, where available) associated with initial procedures and repeat 
procedures (i.e., estimated target lesion revascularizations (TLRs)) were included. 
Average device utilization was informed by RCTs and TLR risk was derived from 
a network meta-analysis. Alternative analyses, including incremental reimburse-
ment for DCBs, or different utilization/comparator assumptions, were also evalu-
ated. Results: When including DCBs into the mix of treatments (1,000 patients) 
one-year cost-savings were estimated to be $74,735 and $104,688 for inpatient and 
outpatient hospital perspectives, respectively. Additionally, DCBs were predicted 
to be cost-saving in the majority of analyses vs. individual therapies (e.g., DCB 
vs. CS: -$2,202 to -$2,967 per patient). Alternative analyses assuming incremental 
reimbursement predicted that DCBs could provide even greater cost-savings under 
a Medicare payment scenario. cOnclusiOns: These analyses suggest that DCBs 
may provide cost-savings from a hospital perspective when considering the full 
range of comparators.
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iMPAct of sAMPle collection MethoD for egfr MutAtion testing: 
results of BlooD-BAseD AnD tissue-BAseD coBAsâ® egfr MutAtion 
testing in the treAtMent of locAlly ADvAnceD or MetAstAtic nsclc 
in the us
Poulios N.1, Hristova-Neeley D.2, Gavaghan M.2
1Roche Molecular Systems, Inc., Pleasanton, CA, USA, 2GfK, Wayland, MA, USA
Objectives: Sufficient tissue sample is not always available for EGFR mutation 
testing to direct treatment with tyrosine kinase inhibitors in NSCLC patients. We 
compared the impact of using the FDA-approved cobas® EGFR Mutation Test alone 
versus using blood-based cobas® EGFR Mutation Test as an alternative test for 
patients without adequate tissue sample in NSCLC patient treatment decision-
making in the US. MethOds: A decision-tree model was developed to compare 
testing methodologies and resulting treatment pathways in a hypothetical NSCLC 
US population health plan with 5 million covered lives and a baseline EGFR muta-
tion prevalence of 16%. Inputs were based on published literature and Medicare 
fee schedule reimbursement. Outcomes of the model included patients with test 
failures, average patient survival time, and budget impact. The combination of tis-
sue and blood-based testing were examined in four different scenarios. Results: 
Blood-based EGFR mutation testing is a more accessible method for identifying 
EGFR mutation status for patients without a tissue sample. More patients received 
Objectives: Mastectomy and lumpectomy procedures are often carried out using 
electrocautery; however, clinical evidence has demonstrated that the use of ultra-
sonic energy may reduce blood loss, seroma formation, wound infection, flap necro-
sis, hematoma, prolonged axillary drainage and length of stay. In the Canadian 
healthcare environment hospitals are faced with increasingly restrictive budgets, 
creating a critical need to demonstrate the cost-effectiveness of new technolo-
gies. This study was conducted to determine whether the reduction in complica-
tions associated with the use of ultrasonic energy in mastectomy and lumpectomy 
procedures offsets the increased device costs in a Canadian hospital. MethOds: 
We examined the budget impact of replacing electrocautery devices with ultra-
sonic energy in a hospital that performs 100 lumpectomies and 100 mastectomies 
annually. The model incorporates the costs associated with surgery, length of stay 
(taking into account facility and staff costs) and postoperative complications. The 
cost data was obtained from the Ontario Case Costing Initiative and case costing 
from a large Canadian hospital. Patient outcomes data was obtained from pooling 
published, peer reviewed literature after completing a comprehensive literature 
review. A multivariate sensitivity analysis was completed to ensure scientific rig-
our. Results: The use of electrocautery in mastectomy and lumpectomy proce-
dures is associated with lower device costs when compared to the use of ultrasonic 
energy devices. However, mastectomies and lumpectomies completed with ultra-
sonic energy devices demonstrate reduced operating time, a reduction in length of 
stay and a reduction in post-operative complications which offsets the increased 
device costs. The model establishes that replacing electrocautery with ultrasonic 
devices in a Canadian hospital performing 100 mastectomies and 100 lumpectomies 
annually would allow for a potential cost avoidance of $171,966. cOnclusiOns: In 
a Canadian hospital, the use of ultrasonic energy in mastectomy and lumpectomy 
procedures provides a cost savings when compared to the use of electrocautery.
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BuDget iMPAct of PercutAneous enDovAsculAr ABDoMinAl AortA 
AneurysM (AAA) rePAir coMPAreD to stAnDArD enDovAsculAr rePAir 
in cAnADiAn hosPitAls
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Objectives: Canadian hospitals spend an estimated $111 million annually on elec-
tive AAA repair. Percutaneous endovascular abdominal aortic repair approach (PEVAR) 
is a new minimally invasive technique that avoids surgical cut down associated with 
standard endovascular AAA repair (EVAR). Innovations in access devices and low pro-
file stent grafts have enabled the PEVAR approach. According to recent studies, PEVAR 
may offer substantial efficiency benefits as well as a reduction in post-operative 
complications and patient pain. The objective of our study was to evaluate the budget 
impact to a hospital of changing the technique for AAA repair from the EVAR approach 
to the PEVAR approach. MethOds: We examined the budget impact of replacing 
the EVAR approach with the PEVAR approach in a Canadian hospital that performs 
100 endovascular AAA repairs annually. The model incorporates the costs associated 
with surgery, length of stay and postoperative complications occurring within 30 
days. The cost data used in the model was obtained from peer reviewed literature, 
the Ontario Case Costing Initiative and case costing from a large Canadian hospital. 
Patient outcomes data was obtained from pooling published prospective studies after 
completing a comprehensive literature review. A multivariate sensitivity analysis was 
completed. Results: The use of PEVAR in AAA repair is associated with increased 
access device costs when compared to the EVAR approach. However, AAA repair com-
pleted with the PEVAR approach demonstrate reduced operating time, a reduction 
in length of stay and time in the recovery room and a reduction in post-operative 
complications which offset the increased device costs. The model establishes that 
switching to the PEVAR approach in a Canadian hospital performing 100 AAA repairs 
annually would result in a potential cost avoidance of $245,130. cOnclusiOns: A 
change in AAA repair technique from EVAR to PEVAR can be a cost-effective solution 
for Canadian hospitals.
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Objectives: Diabetes (DM) is prevalent among hospitalized patients making insulin 
administration a regular practice in acute care. Variability in the method of adminis-
tration leaves room for optimization. A budget impact model was created to evaluate 
the impact of passive SPN on healthcare worker safety and HRU in the acute care 
setting. MethOds: Model inputs include fixed assumptions of insulin waste and 
cost, needle stick injury (NSI) rates from safety syringe (SS) and SPN, nursing time, 
and supply costs. Inputs were obtained from the literature and real-world pilot 
studies. The model compares 4 scenarios using insulin vial with SS versus using 
insulin pens with SPN: 1) SS+10mL vial patient supply, 2) SS+10mL vial floor stock, 
3) SS+3mL vial patient supply, 4) SS+3mL vial floor stock. Results: Using insulin 
pens with SPN reduced NSIs, decreased nursing time, and increased injection sup-
ply cost. Insulin consumption varies based on the scenario and affects economic 
outcomes. When applying real-world data from a 52-bed pilot study to each scenario, 
annual cost savings (+) or expenditures (-) from switching to SPN are as follows: 
1) +$27,622, 2) -$5,951, 3) +$18,730, 4) -$14,485. cOnclusiOns: The cost of NSI 
contributes significantly to total HRU in the acute care setting in the US. Benefits 
of switching to SPN include reducing NSIs and decreasing nursing time needed to 
prepare an insulin injection. For individual patient supply scenarios (scenarios 1 
and 3), switching to SPN can reduce both NSIs and total cost to the institution. It 
is important to note that although the real-world pilot study results above are not 
generalizable, the model is adaptable to any institution based on number of beds 
and yearly insulin consumption. NSI rates may be underestimated, and in these 
cases, adoption of SPN may have a positive budget impact while improving health 
care worker safety.
